ArticleBMC medicine2026
AI-assisted diagnosis of cardiac amyloidosis using electrocardiograms and echocardiography: a multicenter retrospective study in China.
Article in BMC medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundCardiac amyloidosis (CA) is an under-recognized cause of left-ventricular hypertrophy (LVH) that is often misclassified as hypertrophic cardiomyopathy (HCM) or hypertensive heart disease (HHD). We aimed to develop and externally validate an AI model using electrocardiograms (ECG) and echocardiography to distinguish CA from other LVH aetiologies.
methodsA retrospective, multicenter study was conducted, with a derivation cohort collected from PUMCH (290 CA patients, 215 HCM patients, and 160 HHD patients) and an external validation cohort recruited from 10 other hospitals across China (126 CA patients, 240 HCM patients, and 190 HHD patients). Twenty-eight clinical, ECG, and echocardiographic predictors were included, and we selected the top 7 important features by recursive feature elimination strategy. The Super Learner model combines predictions from 11 machine learning models, and model performance was evaluated via macro-AUC, accuracy, precision, F1 score, and etc. We developed a simplified scoring system to diagnose CA, and classifying patients into three groups based on CA probability to minimize misdiagnosis risk.
resultsRanking by feature importance, the top seven features were included and used for model construction, including Sokolow-Lyon index, interventricular septal thickness, systolic blood pressure, left-ventricular posterior wall thickness, tricuspid annular plane systolic excursion, average E/e', and left-ventricular ejection fraction. The Super Learner model, combining Extra Trees, Histogram-based Gradient Boosting, LightGBM, and Multi-Layer Perceptron, achieved the highest AUC of 0.97 (95% confidence interval [CI]: 0.95-0.98). In external validation, the super learner model achieved AUCs of 0.96 (95% CI: 0.95-0.98) for CA, 0.93 (0.91-0.95) for HCM, and 0.91 (0.89-0.94) for HHD. And the simplified scoring system also showed robust diagnostic performance (AUC 0.90, 95% CI 0.86-0.93).
conclusionsWe developed an AI model integrating ECG and echocardiography that provides a clinically applicable and noninvasive framework for CA screening and diagnosis, and implementation through a WeChat-based screening program. However, its performance and generalizability should be further validated in larger prospective multicenter studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.